The FDA accepted Intellia’s BLA for lonvo-z and granted Priority Review, setting a March 10, 2027 target action date. For investors, the application now has a defined regulatory milestone, while approval could make lonvo-z the world’s first in vivo CRISPR-based therapy and only one-time HAE treatment.

Key Highlights

  • The FDA set a March 10, 2027 PDUFA target action date for lonvo-z.
  • The agency is not currently planning an advisory committee meeting for the application.
  • In Phase 3 data, lonvo-z reduced mean monthly HAE attacks by 87% versus placebo.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) has secured FDA acceptance and Priority Review for its Biologics license application for lonvoguran ziclumeran, or lonvo-z. The application is supported by trial data showing an 87% reduction in mean monthly hereditary angioedema attacks versus placebo. The FDA set March 10, 2027, as the PDUFA target action date.

FDA Review Advances Without Advisory Committee

The FDA has told Intellia that it is not currently planning an advisory committee to discuss the application. The BLA covers lonvo-z for hereditary angioedema, a rare genetic disease marked by severe, recurring and unpredictable inflammatory attacks. The therapy was previously known as NTLA-2002. The application is supported by results from Intellia’s global Phase 3 HAELO trial.

Phase 3 Data Show Treatment-Free Response

During the efficacy evaluation period, lonvo-z produced an 87% reduction in mean monthly attacks compared with placebo, with p<0.0001.